CUE · NASDAQ
Cue Biopharma (CUE) Stock Price & Fundamentals
Cue Biopharma (CUE) closed at $370.13 on Oct 9, 2026, up 1.40% from the previous close of $365.02.
Share price, past year
1Y +46.03%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $370.13 |
| Sep 30, 2026 | $374.86 |
| Aug 31, 2026 | $362.50 |
| Jul 31, 2026 | $358.88 |
| Jun 30, 2026 | $344.88 |
| May 29, 2026 | $313.99 |
| Apr 30, 2026 | $305.93 |
| Mar 31, 2026 | $286.34 |
| Feb 27, 2026 | $276.35 |
| Jan 30, 2026 | $260.45 |
| Dec 31, 2025 | $285.39 |
| Nov 28, 2025 | $277.45 |
| Oct 31, 2025 | $270.74 |
Key statistics
- Market cap
- $1.94B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $37.65M
- Net income (TTM)
- −$164.11M
- Shares outstanding
- 5.2M
- Dividend yield
- —
- 52-week range
- $253.20 – $374.86
Cue Biopharma's market cap is $1.94B, based on a share price of $370.13 and 5.2M shares outstanding as of Jun 30, 2026.
Financials
Cue Biopharma reported revenue of $27.47M for fiscal 2025, up 195.75% from fiscal 2024.
Cue Biopharma reported a net loss of $26.60M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 8 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $27.47M | +195.8% | −$26.60M | −96.9% | −$0.28 | −$21.86M |
| FY2024ended Dec 31, 2024 | $9.29M | +69.2% | −$40.67M | −438.0% | −$0.72 | −$36.40M |
| FY2023ended Dec 31, 2023 | $5.49M | +341.0% | −$50.73M | −924.1% | −$1.11 | −$39.96M |
| FY2022ended Dec 31, 2022 | $1.25M | −91.7% | −$53.01M | −4,257.8% | −$1.49 | −$41.98M |
| FY2021ended Dec 31, 2021 | $14.94M | +373.7% | −$44.16M | −295.6% | −$1.41 | −$39.75M |
| FY2020ended Dec 31, 2020 | $3.15M | −8.8% | −$44.78M | −1,419.8% | — | −$33.09M |
| FY2019ended Dec 31, 2019 | $3.46M | +202.7% | −$36.70M | −1,061.2% | — | −$30.84M |
| FY2018ended Dec 31, 2018 | $1.14M | — | −$38.98M | −3,411.5% | — | −$28.27M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $7.88M | −$153.07M | −$24.14 |
| Q1 FY2026ended Mar 31, 2026 | $5.69M | −$5.18M | −$1.08 |
| Q4 FY2025ended Dec 31, 2025 | $21.94M | $1.59M | — |
| Q3 FY2025ended Sep 30, 2025 | $2.15M | −$7.45M | −$0.07 |
| Q2 FY2025ended Jun 30, 2025 | $2.95M | −$8.48M | −$2.67 |
| Q1 FY2025ended Mar 31, 2025 | $421.00K | −$12.26M | −$4.95 |
| Q4 FY2024ended Dec 31, 2024 | $1.58M | −$9.50M | — |
| Q3 FY2024ended Sep 30, 2024 | $3.34M | −$8.66M | −$0.17 |
Company profile
- Name
- Cue Biopharma, Inc.
- Ticker
- CUE
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 100 Chestnut Street, Suite 300, Somerville, MA 02143
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001645460
Recent SEC filings
- Sep 21, 2026
- Aug 14, 2026
- Aug 14, 2026
- Aug 3, 2026
- Jul 10, 2026
- Jun 3, 2026
- Jun 2, 2026
- May 14, 2026
Frequently asked questions
What is Cue Biopharma's stock price?
Cue Biopharma (CUE) closed at $370.13 on Oct 9, 2026, up 1.40% from the previous close of $365.02.
What is Cue Biopharma's market cap?
Cue Biopharma's market cap is $1.94B, based on a share price of $370.13 and 5.2M shares outstanding as of Jun 30, 2026.
How much revenue does Cue Biopharma make?
Cue Biopharma reported revenue of $27.47M for fiscal 2025, up 195.75% from fiscal 2024.
Does Cue Biopharma pay a dividend?
Cue Biopharma's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Cue Biopharma, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures